vs

Side-by-side financial comparison of Penumbra Inc (PEN) and SentinelOne, Inc. (S). Click either name above to swap in a different company.

Penumbra Inc is the larger business by last-quarter revenue ($385.4M vs $258.9M, roughly 1.5× SentinelOne, Inc.). Penumbra Inc runs the higher net margin — 12.3% vs -23.3%, a 35.6% gap on every dollar of revenue. On growth, SentinelOne, Inc. posted the faster year-over-year revenue change (22.9% vs 22.1%). Penumbra Inc produced more free cash flow last quarter ($68.0M vs $20.9M).

Penumbra, Inc. is an American medical device company headquartered in Alameda, California. The company was founded by Arani Bose and Adam Elsesser in 2004. It manufactures devices for interventional therapies to treat vascular conditions such as stroke and aneurysm.

SentinelOne, Inc. is an American cybersecurity company listed on NYSE based in Mountain View, California. The company was founded in 2013 by Tomer Weingarten, Almog Cohen and Ehud ("Udi") Shamir. Weingarten acts as the company's CEO. The company has approximately 2,800 employees and offices in Mountain View, Boston, Prague, Tokyo, and Tel Aviv. The company uses machine learning for monitoring personal computers, IoT devices, and cloud workloads. The company's platform utilizes a heuristic mod...

PEN vs S — Head-to-Head

Bigger by revenue
PEN
PEN
1.5× larger
PEN
$385.4M
$258.9M
S
Growing faster (revenue YoY)
S
S
+0.8% gap
S
22.9%
22.1%
PEN
Higher net margin
PEN
PEN
35.6% more per $
PEN
12.3%
-23.3%
S
More free cash flow
PEN
PEN
$47.1M more FCF
PEN
$68.0M
$20.9M
S

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
PEN
PEN
S
S
Revenue
$385.4M
$258.9M
Net Profit
$47.3M
$-60.3M
Gross Margin
68.0%
73.8%
Operating Margin
15.4%
-28.3%
Net Margin
12.3%
-23.3%
Revenue YoY
22.1%
22.9%
Net Profit YoY
40.6%
23.1%
EPS (diluted)
$1.20
$-0.18

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PEN
PEN
S
S
Q4 25
$385.4M
$258.9M
Q3 25
$354.7M
$242.2M
Q2 25
$339.5M
$229.0M
Q1 25
$324.1M
Q4 24
$315.5M
Q3 24
$301.0M
Q2 24
$299.4M
Q1 24
$278.7M
Net Profit
PEN
PEN
S
S
Q4 25
$47.3M
$-60.3M
Q3 25
$45.9M
$-72.0M
Q2 25
$45.3M
$-208.2M
Q1 25
$39.2M
Q4 24
$33.7M
Q3 24
$29.5M
Q2 24
$-60.2M
Q1 24
$11.0M
Gross Margin
PEN
PEN
S
S
Q4 25
68.0%
73.8%
Q3 25
67.8%
75.0%
Q2 25
66.0%
75.3%
Q1 25
66.6%
Q4 24
66.8%
Q3 24
66.5%
Q2 24
54.4%
Q1 24
65.0%
Operating Margin
PEN
PEN
S
S
Q4 25
15.4%
-28.3%
Q3 25
13.8%
-33.3%
Q2 25
12.0%
-38.2%
Q1 25
12.4%
Q4 24
13.6%
Q3 24
11.7%
Q2 24
-27.0%
Q1 24
4.3%
Net Margin
PEN
PEN
S
S
Q4 25
12.3%
-23.3%
Q3 25
12.9%
-29.7%
Q2 25
13.3%
-90.9%
Q1 25
12.1%
Q4 24
10.7%
Q3 24
9.8%
Q2 24
-20.1%
Q1 24
3.9%
EPS (diluted)
PEN
PEN
S
S
Q4 25
$1.20
$-0.18
Q3 25
$1.17
$-0.22
Q2 25
$1.15
$-0.63
Q1 25
$1.00
Q4 24
$0.88
Q3 24
$0.75
Q2 24
$-1.55
Q1 24
$0.28

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PEN
PEN
S
S
Cash + ST InvestmentsLiquidity on hand
$186.9M
$649.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.4B
$1.5B
Total Assets
$1.8B
$2.4B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PEN
PEN
S
S
Q4 25
$186.9M
$649.8M
Q3 25
$321.0M
$810.8M
Q2 25
$421.8M
$766.9M
Q1 25
$376.1M
Q4 24
$324.4M
Q3 24
$280.5M
Q2 24
$288.3M
Q1 24
$223.1M
Stockholders' Equity
PEN
PEN
S
S
Q4 25
$1.4B
$1.5B
Q3 25
$1.4B
$1.5B
Q2 25
$1.3B
$1.5B
Q1 25
$1.2B
Q4 24
$1.2B
Q3 24
$1.1B
Q2 24
$1.2B
Q1 24
$1.2B
Total Assets
PEN
PEN
S
S
Q4 25
$1.8B
$2.4B
Q3 25
$1.7B
$2.4B
Q2 25
$1.7B
$2.4B
Q1 25
$1.6B
Q4 24
$1.5B
Q3 24
$1.5B
Q2 24
$1.5B
Q1 24
$1.6B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PEN
PEN
S
S
Operating Cash FlowLast quarter
$86.5M
$21.0M
Free Cash FlowOCF − Capex
$68.0M
$20.9M
FCF MarginFCF / Revenue
17.7%
8.1%
Capex IntensityCapex / Revenue
4.8%
0.0%
Cash ConversionOCF / Net Profit
1.83×
TTM Free Cash FlowTrailing 4 quarters
$174.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PEN
PEN
S
S
Q4 25
$86.5M
$21.0M
Q3 25
$58.3M
$-1.0M
Q2 25
$44.9M
$52.3M
Q1 25
$49.0M
Q4 24
$51.1M
Q3 24
$56.5M
Q2 24
$22.6M
Q1 24
$38.3M
Free Cash Flow
PEN
PEN
S
S
Q4 25
$68.0M
$20.9M
Q3 25
$42.0M
$-1.3M
Q2 25
$29.4M
$52.1M
Q1 25
$35.5M
Q4 24
$45.7M
Q3 24
$51.0M
Q2 24
$18.1M
Q1 24
$32.5M
FCF Margin
PEN
PEN
S
S
Q4 25
17.7%
8.1%
Q3 25
11.8%
-0.5%
Q2 25
8.7%
22.8%
Q1 25
11.0%
Q4 24
14.5%
Q3 24
16.9%
Q2 24
6.0%
Q1 24
11.7%
Capex Intensity
PEN
PEN
S
S
Q4 25
4.8%
0.0%
Q3 25
4.6%
0.1%
Q2 25
4.6%
0.1%
Q1 25
4.2%
Q4 24
1.7%
Q3 24
1.8%
Q2 24
1.5%
Q1 24
2.1%
Cash Conversion
PEN
PEN
S
S
Q4 25
1.83×
Q3 25
1.27×
Q2 25
0.99×
Q1 25
1.25×
Q4 24
1.52×
Q3 24
1.91×
Q2 24
Q1 24
3.48×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PEN
PEN

Thrombectomy$254.7M66%
Other$130.7M34%

S
S

US$154.8M60%
Non Us$104.1M40%

Related Comparisons